Table 3.
Specificity of BinaxNOW® urine pneumococcal antigen test among adults without fever or cough, Asembo, Kenya.
| All adults (N = 660) | Adults colonized with pneumococci in nasopharynx or oropharynx (N = 244) | Adults not colonized with pneumococci in nasopharynx or oropharynx (N = 416) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Patient characteristics: | Negative Tests/Total Tests Performed | % | (95%CI) | Negative Tests/Total Tests Performed | % | (95% CI) | Negative Tests/Total Tests Performed | % | (95% CI) |
|
| |||||||||
| Total | 645/660 | 98 | (96–99) | 236/244 | 97 | (94–99) | 409/416 | 98 | (97–99) |
| HIV-infected | 356/364 | 98 | (96–99) | 145/149 | 97 | (93–99) | 211/215 | 98 | (95–99) |
| HIV-uninfected | 105/109 | 96 | (91–99) | 29/31 | 94 | (79–99) | 76/78 | 97 | (91–100) |
| HIV Unknown | 184/187 | 98 | (95–100) | 62/64 | 97 | (89–100) | 122/123 | 99 | (96–100) |
| Aged15–30 Years | 298/307 | 97 | (95–99) | 127/133 | 95 | (90–98) | 171/174 | 98 | (95–100) |
| Aged 31–45 Years | 305/311 | 98 | (96–99) | 102/104 | 98 | (93–100) | 203/207 | 98 | (95–99) |
| Aged >45 Years | 42/42 | 100 | (92–100) | 7/7 | 100 | (59–100) | 35/35 | 100 | (90–100) |
| Male | 222/223 | 100 | (98–100) | 74/74 | 100 | (95–100) | 148/149 | 99 | (96–100) |
| Female | 423/437 | 97 | (95–98) | 162/170 | 95 | (91–98) | 261/267 | 98 | (95–99) |